Researchers analyzed data from the Taiwan National Health Insurance Research Database and Cancer Registry to understand outcomes for people with renal cell carcinoma. The study included 14,131 cases diagnosed between 1998 and 2016, comparing patients who received targeted therapy against those who received non-targeted therapy. The team looked at life expectancy, loss of life expectancy, and lifetime medical costs over a lifetime follow-up period.
For patients with advanced disease, the study found that life expectancy was 4.43 years for those on targeted therapy and 3.63 years for those on non-targeted therapy. However, the difference between these groups was not significant, indicating similar outcomes regardless of the specific therapy type used in this real-world setting. The study also noted that the rate of new kidney cancer diagnoses increased for both men and women during the observation period.
No safety concerns, adverse events, or discontinuations were reported in this dataset. The authors suggest that current clinical practices might not be as efficient as hoped. They recommend re-evaluating how treatments are reimbursed and considering genomic profiling to move toward more effective combination therapies. Readers should view this as an observational look at real-world data rather than a definitive proof of one treatment working better than another.
